CalciMedica regained compliance with Nasdaq’s minimum bid-price requirement after its common stock maintained a closing bid of at least $1.00 per share from August 31 through September 14, 2026. The company said it has no outstanding deficiency notices from Nasdaq, removing the specific listing deficiency identified in March.

Key Highlights

  • Nasdaq notified CalciMedica on September 15 that its common stock met the required bid-price standard from August 31 through September 14.
  • The Nasdaq notice CalciMedica received on March 16 concerned a minimum bid price below $1.00 per share.
  • CalciMedica said it has no outstanding deficiency notices from Nasdaq as of September 16.

CalciMedica, Inc. (NASDAQ: CALC) has regained compliance with Nasdaq’s minimum bid-price requirement after its common stock recorded a closing bid of at least $1.00 per share through the required review period. Nasdaq’s Listing Qualifications Department notified the company that it had regained compliance, and the company had no outstanding deficiency notices as of September 16, 2026.

Nasdaq Confirms $1.00 Bid-Price Compliance

The issue began with a Nasdaq notice received on March 16, 2026, stating that CalciMedica’s minimum bid price for its common stock had been below the $1.00-per-share minimum required under Listing Rule 5550(a)(2) for 30 consecutive Business days. Nasdaq later determined that the stock’s closing bid price had been at $1.00 per share or higher from August 31 through September 14, 2026. The company received that determination on September 15.